Michael P. Dwyer
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Ubiquitin and proteasome pathways, Protein Structure and Dynamics, HIV/AIDS drug development and treatment, Hepatitis C virus research
Most-Cited Works
- → Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor(2010)557 cited
- → Enantioselective Intramolecular Cyclopropanations of Allylic and Homoallylic Diazoacetates and Diazoacetamides Using Chiral Dirhodium(II) Carboxamide Catalysts(1995)215 cited
- → Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases(2010)175 cited
- → Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening(2011)171 cited
- → Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist(2007)127 cited
- → Discovery of 2-Hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist(2006)113 cited
- → Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2(2010)74 cited
- → Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 1(2010)68 cited
- → Structure‐guided discovery of cyclin‐dependent kinase inhibitors(2007)67 cited
- → Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2(2007)65 cited